Star Therapeutics' investigational monoclonal antibody, VGA039, has gained fast track designation from the US Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD).
Brii Biosciences (Brii Bio) has entered into an agreement to acquire the intellectual property and other assets related to the Hepatitis B immunotherapeutic candidate, BRII-179 from VBI Vaccines (VBI) and its creditor K2 VBI Equity Trust and K2 HealthVentures.
WuXi Biologics (WuXi Bio) and Sino Biopharm have entered into a service agreement for the discovery of a monoclonal antibody (mAb) for a target that is not disclosed.
Axcelead Drug Discovery Partners (Axcelead DDP) has signed a drug discovery service agreement with Astellas Pharma for new candidate compounds for targeted protein degraders.
Bio-Thera Solutions has entered into a partnership with Astra Industrial Group subsidiary, Tabuk Pharmaceutical Manufacturing Company, to bring BAT2206, Jansen's Stelara (ustekinumab) biosimilar, to the Saudi Arabian market.
Basilea Pharmaceutica has received an additional $7.3m from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its antibiotic candidate, BAL2420, towards first-in-human clinical trials expected by mid-2026.
WuXi Biologics, in partnership with Hangzhou DAC Biotechnology, has entered into a research service agreement with Aadi Bioscience for antibody-drug conjugates (ADCs).
Assembly Biosciences has received an investment from Gilead Sciences, comprising a $20.1m equity investment and $10m in accelerated funding, to propel the clinical development of new antiviral therapies targeting herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV).
The European Commission (EC) has adopted a positive decision for designating Agios Pharmaceuticals’ oral, small molecule pyruvate kinase (PK) activator, mitapivat, as an orphan medicinal product (OMP) for treating sickle cell disease.
Akamis Bio has secured $60m in funding, marking the close of a Series A Prime financing round, which will propel the development of its clinical candidate, NG-350A, for treating locally advanced rectal cancer (LARC), through study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.